# Levothyroxine Sodium - (100 mcg/vial and 500 mcg/vial)

| | | | |
|---|---|---|---|
| **Generic Name** | Levothyroxine sodium | **Innovator** | Fresenius Kabi |
| **Dosage** | 100 mcg/vial and 500 mcg/vial | **Branded US Sales** | Less Than $1000 mn |
| **Probable FTF** | Less Than 5 | **Known Para IV Filers** | More Than 5 |
| **Other ANDA developers** | Less Than 5 | **Tentative Approvals** | None |
| **Final Approvals** | More Than 5 | **Generic Launches** | Less Than 5 |
| **Indication** | Indicated for the treatment of myxedema coma | | |
| **Complexities** | Yes | | |

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

## Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

## Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

## Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

# Levothyroxine Sodium - (200mcg/vial)

| | | | |
|---|---|---|---|
| **Generic Name** | Levothyroxine sodium | **Innovator** | Fresenius Kabi |
| **Dosage** | 200mcg/vial | **Branded US Sales** | Less Than $1000 mn |
| **Probable FTF** | Less Than 5 | **Known Para IV Filers** | Less Than 5 |
| **Other ANDA developers** | Less Than 5 | **Tentative Approvals** | None |
| **Final Approvals** | Less Than 5 | **Generic Launches** | Less Than 5 |
| **Indication** | Indicated for the treatment of myxedema coma | | |
| **Complexities** | Yes | | |

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

## Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

## Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

## Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

# Levothyroxine Sodium - (100 mcg/5 mL (20 mcg/mL), 200 mcg/5 mL (40 mcg/mL), and 500 mcg/5 mL (100 mcg/mL) ; Solution, Intravenous)

| | | | |
|---|---|---|---|
| **Generic Name** | Levothyroxine sodium | **Innovator** | Fresenius Kabi |
| **Dosage** | 100 mcg/5 mL (20 mcg/mL), 200 mcg/5 mL (40 mcg/mL), and 500 mcg/5 mL (100 mcg/mL) ; Solution, Intravenous | **Branded US Sales** | Less Than $1000 mn |
| **Probable FTF** | None | **Known Para IV Filers** | Less Than 5 |
| **Other ANDA developers** | Less Than 5 | **Tentative Approvals** | None |
| **Final Approvals** | None | **Generic Launches** | None |
| **Indication** | Levothyroxine Sodium Injection is L-thyroxine (T4) indicated in adult patients for the treatment of myxedema coma. | | |
| **Complexities** | Yes | | |

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

## Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

## Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

## Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

# Levothyroxine Sodium - (0.1MG/1ML ; Solution)

| | | | |
|---|---|---|---|
| **Generic Name** | Levothyroxine sodium | **Innovator** | Hikma |
| **Dosage** | 0.1MG/1ML ; Solution | **Branded US Sales** | Less Than $1000 mn |
| **Probable FTF** | None | **Known Para IV Filers** | None |
| **Other ANDA developers** | Less Than 5 | **Tentative Approvals** | None |
| **Final Approvals** | None | **Generic Launches** | None |
| **Indication** | Levothyroxine Sodium is an L-thyroxine product. Levothyroxine (T4) Sodium Injection is indicated for the treatment of myxedema coma. ( | | |
| **Complexities** | Yes | | |

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

## Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

## Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

## Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.